NCT06528301 - A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions

Lymphoma, B-CellLymphoma, Non-Hodgkin (NHL)Lymphoma, Large B-Cell, Diffuse (DLBCL)Chronic Lymphocytic Leukemia (CLL)

Interventions

GENETIC

UB-VV111

UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.

DRUG

rapamycin

Rapamycin is an FDA-approved drug.

Trial Locations (8)

RECRUITING

Royal North Shore Hospital, Saint Leonards

RECRUITING

St. Vincent's Hospital Melbourne, Fitzroy

RECRUITING

University of Cincinnatti Medical Center, Cincinnatti

RECRUITING

The David and Etta Jonas Center for Cellular Therapy, Chicago

RECRUITING

Washington University School of Medicine/Siteman Cancer Center, St Louis

NOT_YET_RECRUITING

City of Hope, Duarte

RECRUITING

Fred Hutch Cancer Center, Seattle

RECRUITING

University of Nebraska Medical Center, Omaha